Immunocytokines Market Report 2026

The immunocytokines market size has grown strongly in recent years. It will grow from $3.56 billion in 2025 to $3.88 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to limited availability of targeted immunocytokine therapies, reliance on conventional cytokine treatments, growing oncology and autoimmune research, increasing clinical trials for cytokine therapies, adoption of basic immune-modulating treatment protocols.

The immunocytokines market size is expected to see strong growth in the next few years. It will grow to $5.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to development of recombinant and modified interleukins, expansion of tumor necrosis factor-based immunocytokines, increasing investment in antibody-cytokine fusion proteins, rising adoption in personalized cancer and autoimmune therapy, integration of immune modulators with advanced delivery systems. Major trends in the forecast period include rising adoption of immunocytokines in targeted cancer therapies, growth in research on cytokine-based immunotherapies for autoimmune diseases, increasing focus on reducing systemic toxicity through targeted delivery, expansion of specialty clinics and research institutes using immunocytokines, development of fusion proteins combining cytokines with novel antibody formats.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the immunocytokines market in the future. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own healthy cells and tissues. This rise is largely linked to greater exposure to environmental pollutants, which can disrupt immune function and trigger immune responses against the body’s own tissues. Immunocytokines provide a solution by combining targeted immune modulation with precision delivery, reducing systemic side effects. They improve treatment outcomes by directing cytokines specifically to affected tissues, enhancing both safety and effectiveness. For example, in February 2024, Arthritis Australia, a non-profit organization, estimated that 562,378 Australians will be living with rheumatoid arthritis (RA) in 2025, representing 14% of all arthritis cases. By 2040, this figure is projected to increase by 33% to 748,721, adding 186,343 new cases compared with 2025. Thus, the growing prevalence of autoimmune diseases is fueling demand for immunocytokines.

Companies in the immunocytokines market are focusing on innovative approaches such as antibody cytokine fusion proteins to enable targeted cytokine delivery, enhance therapeutic efficacy, and minimize systemic toxicity. These fusion proteins are engineered molecules that combine the targeting ability of antibodies with the immune-modulating effects of cytokines, delivering therapy directly to diseased tissues like tumors or inflamed areas. For instance, in July 2023, SunHo BioPharmaceutical Co. Ltd., a biopharmaceutical company based in China, introduced IBB0979 (B7H3-IL-10 immunocytokine), a novel antibody-cytokine fusion protein for treating advanced or metastatic solid tumors, now in Phase I/II clinical trials. This drug integrates the tumor-targeting properties of the B7H3 antibody with the anti-inflammatory and immune-modulating effects of interleukin-10 (IL-10). By delivering IL-10 specifically to B7H3-expressing tumor cells, IBB0979 modifies the tumor microenvironment, reduces inflammation, and strengthens the immune response against cancer, offering a potential new therapy for hard-to-treat solid tumors.

In June 2023, Philogen S.p.A., an Italy-based biotechnology company, entered into a partnership with Merck & Co., Inc. (MSD) to advance oncology clinical trials. Through this collaboration, Philogen and MSD seek to assess new therapeutic candidates by integrating Philogen’s tumor-targeted antibody-cytokine fusion proteins with MSD’s clinical development capabilities, thereby accelerating the collection of safety and efficacy data, improving patient selection, and supporting the potential commercialization of next-generation cancer treatments. Merck & Co., Inc. (MSD) is a US-based pharmaceutical company focused on the development and commercialization of innovative medicines and vaccines in oncology, infectious diseases, and other therapeutic areas.

Major companies operating in the immunocytokines market are Xencor Inc., Philogen S.p.A, Cytimmune Sciences Inc., Cytune Pharma S.A.S.

North America was the largest region in the immunocytokines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunocytokines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunocytokines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the immunocytokines market by raising costs for imported biologics, cytokines, and fusion protein development kits, which has affected supply chains and increased therapy costs. Segments such as interleukins, interferons, and tumor necrosis factor fusion proteins are particularly affected, especially in regions like North America, Europe, and Asia-Pacific hubs including China and India. On the positive side, tariffs have encouraged local production, investment in domestic R&D, and innovation in cost-efficient immunocytokine therapies.

The immunocytokines market research report is one of a series of new reports that provides immunocytokines market statistics, including immunocytokines industry global market size, regional shares, competitors with a immunocytokines market share, detailed immunocytokines market segments, market trends and opportunities, and any further data you may need to thrive in the immunocytokines industry. This immunocytokines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immunocytokines are engineered fusion proteins that combine cytokines with antibodies or antibody fragments. Their primary purpose is to deliver immune-stimulating cytokines directly to specific cells or tissues, enhancing the immune response against diseases such as cancer while reducing systemic side effects. This targeted approach improves the therapeutic efficacy of cytokines while minimizing systemic toxicity.

The main product types of immunocytokines include interleukins, interferons, tumor necrosis factors, and others. Interleukins are a group of cytokines, or signaling proteins, mainly produced by white blood cells, which play a vital role in regulating immune responses, inflammation, and blood cell development. Their mechanisms of action include acting as antagonists, agonists, or immune modulators, and they are applied in conditions such as cancer, autoimmune diseases, infectious diseases, and more. Key end users include hospitals, research institutes, specialty clinics, and other healthcare facilities.

The immunocytokines market consists of sales of body-cytokine fusion proteins, IL-2-based immunocytokines, and IL-12-based immunocytokines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.